7 results on '"Elenitsas, Rosalie"'
Search Results
2. Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy.
- Author
-
Bartlett, Edmund, Gimotty, Phyllis, Sinnamon, Andrew, Wachtel, Heather, Roses, Robert, Schuchter, Lynn, Xu, Xiaowei, Elder, David, Ming, Michael, Elenitsas, Rosalie, Guerry, DuPont, Kelz, Rachel, Czerniecki, Brian, Fraker, Douglas, and Karakousis, Giorgos
- Abstract
Background: The role for sentinel lymph node biopsy (SLNB) in patients with thin melanoma (≤1 mm) remains controversial. We examined a large cohort of patients with thin melanoma to better define predictors of SLN positivity. Methods: From 1995 to 2011, 781 patients with thin primary melanoma and evaluable clinicopathologic data underwent SLNB at our institution. Predictors of SLN positivity were determined using univariate and multivariate regression analyses, and patients were risk-stratified using a classification and regression tree (CART) analysis. Results: In the study cohort ( n = 781), 29 patients (3.7 %) had nodal metastases. In the univariate analysis, mitotic rate [odds ratio (OR) = 8.11, p = 0.005], Clark level (OR 4.04, p = 0.003), and thickness (OR 3.33, p = 0.011) were significantly associated with SLN positivity. In the multivariate analysis, MR (OR 7.01) and level IV-V (OR 3.45) remained significant predictors of SLN positivity. CART analysis initially stratified lesions by mitotic rate; nonmitogenic lesions ( n = 273) had a 0.7 % SLN positivity rate versus 5.6 % in mitogenic lesions ( n = 425). Mitogenic lesions were further stratified by Clark level; patients with level II-III had a 2.9 % SLN positivity rate ( n = 205) versus 8.2 % with level IV-V ( n = 220). With median follow-up of 6.3 years, five SLN-negative patients developed nodal recurrence and four SLN-positive patients died of disease. Conclusions: SLN positivity is low in patients with thin melanoma (3.7 %) and exceedingly so in nonmitogenic lesions (0.7 %). Appreciable rates of SLN positivity can be identified in patients with mitogenic lesions, particularly with concurrent level IV-V regardless of thickness. These factors may guide appropriate selection of patients with thin melanoma for SLNB. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
3. Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas.
- Author
-
Cintolo, Jessica, Gimotty, Phyllis, Blair, Anne, Guerry, DuPont, Elder, David, Hammond, Rachel, Elenitsas, Rosalie, Xu, Xiaowei, Fraker, Douglas, Schuchter, Lynn, Czerniecki, Brian, and Karakousis, Giorgos
- Abstract
Background: Tumor infiltrating lymphocytes (TIL) and histological regression in primary melanoma are generally considered indicators of the local immune response but their roles as prognostic factors have been variably reported. We examined the prognostic role of these variables in patients with high risk (T4) primary melanomas in a large series of patients with long-term follow-up. Methods: From a prospectively maintained cohort of patients diagnosed between 1971 and 2004, 161 patients were retrospectively identified with primary thick melanomas (>4 mm), no clinical evidence of regional nodal disease (RND) at diagnosis and complete histopathologic data. Univariate and multivariate Cox regression models were performed to identify clinical and histopathologic predictors of disease-specific survival (DSS) and to identify subgroups with differential survival. Results: Factors significantly associated with decreased DSS by univariate analysis included male gender, age ≥ 60 years, axial anatomic location, presence of ulceration, RND, absence of TIL, and presence of regression. In the final multivariate model, TIL and regression, as interacting variables, and RND status remained significantly associated with DSS. In the presence of TIL, concomitant regression was associated with significantly worse survival ( p ≤ 0.0001). In the absence of TIL, there was no effect of regression on survival ( p = 0.324). Conclusions: Primary TIL and regression status and RND status are independently associated with melanoma-specific survival in patients with T4 melanomas; presence of TIL in the primary melanoma with concomitant radial growth phase regression is associated with a poor prognosis and may reflect an ineffective local regional immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Regional Nodal Metastatic Disease Is the Strongest Predictor of Survival in Patients with Thin Vertical Growth Phase Melanomas: A Case for SLN Staging Biopsy in These Patients.
- Author
-
Karakousis, Giorgos, Gimotty, Phyllis, Czerniecki, Brian, Elder, David, Elenitsas, Rosalie, Ming, Michael, Fraker, Douglas, Guerry, DuPont, and Spitz, Francis
- Abstract
The benefit of sentinel lymph node (SLN) biopsy for patients with thin (≤1.0 mm) melanomas, even for prognostic value, is controversial. This may partly result from the relatively small number and short follow-up of SLN-positive patients in this group. Previously, we have shown that clinical regional nodal metastatic disease (RNMD) serves as a good surrogate for SLN positivity. Here, we use RNMD as a validated surrogate for SLN positivity and examine its prognostic value in a large pre-SLN group of patients with thin vertical growth phase (VGP) lesions who would today commonly be offered SLN biopsy in our practice. Between 1972 and 1991, 472 patients with thin VGP melanomas with at least 10 years’ follow-up were eligible for the study. Kaplan-Meier survival curves were computed for patients with and without RNMD. A multivariate Cox model and classification tree analysis were used to evaluate clinical and histopathologic predictors of survival. Sixty-seven patients (14.2%) developed recurrence, 53.7% of whom developed RNMD. Forty-five patients (9.5%) experienced melanoma-related deaths (MRD). The most statistically significant predictor of MRD was RNMD (hazard ratio [HR] 13.5, P < .0001). Thickness (HR 10.5, P = .004), axial location (HR 4.6, P = .001), and age >60 years (HR 2.7, P = .005) additionally were independently associated with an increased risk of MRD. RNMD patients demonstrated a 44.4% 10-year disease-specific mortality. RNMD was the most statistically significant factor associated with MRD in patients with thin VGP lesions. This supports the prognostic use of SLN biopsy in this group, recognizing that additional factors, including thickness, axial location, and older age were independently associated with a worse survival outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
5. Predictors of Regional Nodal Disease in Patients With Thin Melanomas.
- Author
-
Karakousis, Giorgos, Gimotty, Phyllis, Botbyl, Jeffrey, Kesmodel, Susan, Elder, David, Elenitsas, Rosalie, Ming, Michael, Guerry, DuPont, Fraker, Douglas, Czerniecki, Brian, and Spitz, Francis
- Abstract
Most melanoma patients present with thin (≤1.0 mm) lesions. Indications for sentinel lymph node (SLN) biopsy are not well defined for this group. Previously, we reported an association between mitotic rate (MR) and SLN positivity in these patients. The study was limited by a relatively small sample size and low statistical power. In this study, we evaluated a large population of patients with thin melanoma from the pre-SLN era to identify predictors of regional nodal disease (RND) that may serve as a surrogate for SLN positivity. Eight hundred eighty-two patients evaluated between 1972 and 1991 were included in the study. Univariate and multivariate regression analyses were performed by using clinical and histological data to identify factors associated with RND. A multivariate logistic regression model was developed and applied to the previously reported group of patients with thin melanomas who underwent SLN biopsy between 1996 and 2004 for validation. Thirty-eight patients (4.3%) had evidence of RND. In the multivariate analysis, a MR >0, vertical growth phase (VGP), male sex, and ulceration were statistically significant predictors of RND. Patients at the highest risk according to a classification tree analysis (VGP and MR >0) had an RND rate of 11.9%. The regression model developed predicted well the SLN status in the validation sample. Investigation of a large pre-SLN population identified MR >0, ulceration, VGP, and male sex as independently predictive of RND in patients with thin melanomas. These factors may help to identify subgroups of these patients that have clinically significant risks of SLN positivity. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. Incidence of Sentinel Node Metastasis in Patients With Thin Primary Melanoma (#1 mm) With Vertical Growth Phase.
- Author
-
Bedrosian, Isabelle, Faries, Mark, Guerry IV, DuPont, Elenitsas, Rosalie, Schuchter, Lynn, Mick, Rosemarie, Spitz, Francis, Bucky, Louis, Alavi, Abass, Elder, David, Fraker, Douglas, and Czerniecki, Brian
- Abstract
Background: Patients with thin primary melanomas (#1 mm) generally have an excellent prognosis. However, the presence of a vertical growth phase (VGP) adversely impacts the survival rate. We report on the rate of occurrence of nodal metastasis in patients with thin primary melanomas with a VGP who are offered sentinel lymph node (SLN) biopsy. Methods: Among 235 patients with clinically localized cutaneous melanomas who underwent successful SLN biopsy, 71 had lesions 1 mm or smaller with a VGP. The SLN was localized by using blue dye and a radiotracer. If negative for tumor by using hematoxylin and eosin staining, the SLN was further examined by immunohistochemistry. Results: The rate of occurrence of SLN metastasis was 15.2% in patients with melanomas deeper than 1 mm and 5.6% in patients with thin melanomas. Three patients with thin melanomas and a positive SLN had low-risk lesions, based on a highly accurate six-variable multivariate logistic regression model for predicting 8-year survival in stage I/II melanomas. The fourth patient had a low- to intermediate-risk lesion based on this model. At the time of the lymphadenectomy, one patient had two additional nodes with metastasis. Conclusions: VGP in a melanoma 1 mm or smaller seems to be a risk factor for nodal metastasis. The risk of nodal disease may not be accurately predicted by the use of a multivariate logistic regression model that incorporates thickness, mitotic rate, regression, tumor-infiltrating lymphocytes, sex, and anatomical site. Patients with thin lesions having VGP should be evaluated for SLN biopsy and trials of adjuvant therapy when stage III disease is found. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
7. Gene expression of RNA for b3 integrin and CD9 in malignant melanoma and melanocytic nevi, evaluated by cDNA expression array profiling.
- Author
-
Van Belle, Patricia A., Satyamoorthy, Kapaettu, Elenitsas, Rosalie, Strzelecki, Donna, Tahin, Paulo, Lei, Hanqin, Herlyn, Meenhard, and Elder, David E.
- Subjects
GENE expression ,RNA ,INTEGRINS ,CD antigens - Abstract
Presents an abstract for the article on the gene expression of RNA for beta 3 integrin and CD9 antigen in malignant melanoma and melanocytic nevi.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.